2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4298 Integrated genetic and endothelial risk stratification identifies distinct outcomes after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms

Alejandro Avendaño Pita, Estefanía Pérez López2, Vázquez López Lourdes, MD3, Ana Belén Gálvez Ruiz4, Pedro Chorao5, Marina Cornejo6, Maria Queralt Salas, Ph.D7, Marta Luque8, Sara Redondo Velao9, Adolfo Sáez Marín, MD10, Félix López-Cadenas11, María José Jiménez12, Guillermo Martin13, Jose Antonio Farah Gamarra14, Felipe Peña-Muñoz, MD15, Manuel Perez Encinas16, Sara Villar, MD17, Sara Labari18, María Huguet19, Joud Zanabili20, Ana Mellado Puiggròs Jr, MD21, Juan Francisco López Rodriguez22, Maria del Mar Perera Álvarez23, Fermin Sanchez-Guijo, MD, PhD24, Silvia Filaferro25, Pascual Balsalobre26, Maria Pascual, MD27, Maria Diez-Campelo, MD, PhD28, Lucia Lopez Corral, MD, PhD29
1 Hospital Universitario de Salamanca / Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
2 Hospital Universitario de Salamanca / Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
3 Hospital Universitario de Salamanca / Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
4 Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain
5 Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain
6 Hospital Clinic de Barcelona, ICAMS, IDIBAPS, Barcelona, Spain
7 Hospital Clinic de Barcelona, ICAMS, IDIBAPS, Barcelona, Spain
8 Hospital Regional de Málaga, Malaga, Spain
9 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
10 Hospital Universitario 12 de Octubre, Madrid, Spain
11 Hospital Universitari Vall d'Hebrón de Barcelona VHIO, Barcelona, Spain
12 Hospital Universitari Germans Trias i Pujol, Badalona, Spain
13 Hospital Universitario Marques de Valdecilla, Santander, Spain
14 Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
15 Institut Català d'Oncologia (ICO) L'Hospitalet del Llobregat, L'Hospitalet del Llobregat, Spain
16 Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
17 Clínica Universidad de Navarra, Pamplona, Spain
18 Hospital Universitario de Navarra, Pamplona, Spain
19 Hospital Universitari Germans Trias i Pujol, Badalona, Spain
20 Hospital Universitario Central de Asturias, Spain, Oviedo, Spain
21 Institut Català d'Oncologia (ICO) L'Hospitalet del Llobregat, L'Hospitalet del Llobregat, Spain
22 Hospital Universitario Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
23 Hospital Universitario Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
24 Hospital Universitario de Salamanca / Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
25 Grupo Español de Trasplante Hematopoyético y Terapia Celular, Madrid, Spain
26 Grupo Español de Trasplante Hematopoyético y Terapia Celular, Madrid, Spain
27 Hospital Regional de Málaga, Malaga, Spain
28 Hospital Universitario de Salamanca / Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
29 Hospital Universitario de Salamanca / Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain

Background

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are rare and biologically heterogeneous myeloid malignancies for which allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative treatment. However, disease-specific models integrating clonal complexity, genetic risk and host vulnerability are lacking. We aimed to identify pre-transplant prognostic factors and determine whether their integration, followed by reassessment at day +100, could provide dynamic risk stratification.

Methods

We retrospectively analyzed adults undergoing first allo-HCT for MDS/MPN at 15 Spanish centers from GETH-TC. Clinical, cytogenetic, molecular and transplant-related variables were collected. Overall survival (OS) was estimated using Kaplan–Meier methodology, and prognostic factors were evaluated using Cox regression. For an exploratory practical risk model, EASIX was dichotomized and integrated with high-risk cytogenetics and ≥4 somatic mutations. A day +100 landmark analysis evaluated the added prognostic value of early disease response.

Results

A total of 212 patients were included: chronic myelomonocytic leukemia (CMML), 75.8%; MDS/MPN with neutrophilia, 11.4%; MDS/MPN-NOS, 10.4%; and MDS/MPN with SF3B1 mutation and thrombocytosis, 2.4%. Median leukocyte count, hemoglobin (g/dL), platelet count (/uL), and marrow blasts (%) were 14.7×10?/L, 10.9 g/dL, 117×10?/L, and 4%, respectively; 35.2% had splenomegaly, 11.2% prior blast transformation, and 12.5% high-risk cytogenetics.

Among 171 (81,1%) molecularly characterized patients, the median mutation count was 3 (range, 0–9), with ≥4 mutations in 45.9%; recurrent mutations included ASXL1 (43%), TET2 (38%), SRSF2 (36%), RUNX1 (22%), NRAS (19%), and SETBP1 (17%). Before allo-HCT, 98 patients received hypomethylating agents, 47 intensive AML-like chemotherapy, and 12 venetoclax-HMA combinations (not mutually exclusive); 34.0% were in CR at the time of allo-HCT. Reduced-intensity conditioning was used in 66.7%.Median follow-up was 48.2 months. One-, three- and five-year OS were 65.0%, 50.5% and 43.1%, respectively.

EASIX was significantly associated with mortality as a continuous variable (HR 1.17; P=0.024). In the multivariable pre-transplant model, ≥4 mutations independently predicted inferior OS (HR 2.33;  P=0.001), while high-risk cytogenetics showed a clinically relevant adverse effect (HR 1.69;  P=0.151).

The exploratory model assigning one point each for ≥4 mutations, high-risk cytogenetics, and EASIX > 3.7 (previously reported) identified low-, intermediate-, and high-risk groups with significantly different OS (P<0.0001), with three-year OS rates of 81.6%, 45.7%, and 40.5%, respectively.

At day +100, 153/185 evaluable patients (82.7%) achieved CR. Among 184 patients alive and followed beyond day +100, failure to achieve complete remission was associated with a fivefold higher subsequent mortality risk (HR 5.16; P<0.000001). Baseline risk remained independently prognostic after incorporating day +100 response (HR per point 1.83;  P=0.00028), yielding a C-index of 0.741.

Relapse/progression occurred in 62/192 evaluable patients (32.3%). Relapse management was documented in 44 cases and included HMA-based therapy (n=23), venetoclax combinations (n=14), donor lymphocyte infusion (n=12), and intensive chemotherapy (n=9); eight patients underwent second allo-HCT. Overall, 109/208 (52,4%) patients died. Among deaths with assigned cause, relapse/progression accounted for 34.7%, infection 28.6%, GVHD 9.2%, bleeding 3.1%, and other causes 24.5%. Crude day +100 and overall transplant-related mortality were 11.3% and 29.2%, respectively. Early NRM did not differ significantly across transplant eras, whereas overall crude NRM decreased from 47.5% in 2010–2019 to 20.8% in the contemporary cohort (P<0.001).

Conclusions

Molecular complexity, cytogenetic risk and endothelial stress capture complementary dimensions of pre-transplant risk in MDS/MPN. EASIX behaves as a continuous prognostic marker without a clear intrinsic threshold, supporting its continuous use in regression models. Early response at day +100 substantially refines prognosis but does not erase baseline biological risk, supporting a dynamic framework integrating pre-transplant biology with post-transplant disease response.

 

Alejandro Avendaño Pita: GSK - Honoraria; CSL Behring - Honoraria; Pfizer - Honoraria; Gilead science - Honoraria; Shionogi - Honoraria; Blueprint Medicines - Honoraria